Other Events ·
Nasdaq notifies Lantern Pharma its stock is not in compliance with the $35 million market value minimum for listed securities
LTRNLantern Pharma Inc.
Lantern Pharma Inc. received notice from Nasdaq on September 25, 2026, that its common stock is not in compliance with Listing Rule 5550(b)(2) because the market value of listed securities fell below the $35 million minimum for 30 consecutive business days. The company has until March 24, 2027, to regain compliance by achieving a closing market value of at least $35 million for 10 consecutive business days. Failure to meet this requirement may result in delisting from the Nasdaq Capital Market. Lantern Pharma Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of oncology treatments.